ANNOUNCING MEDIPHARM LABS AS AN OFFICIAL SPONSOR FOR THE 2020 PROHIBITION PARTNERS LIVE
MediPharm Labs – the global leader in pharma-quality cannabinoid-based products delivers on its promise in the production of pharmaceutical grade cannabis oils, concentrates, and advanced derivative products. Founded in Canada in 2015, MediPharm’s production utilizes a Good Manufacturing Practices certified facility with ISO standard-built clean rooms.
“MediPharm Labs is thrilled to be a sponsor at this global cannabis event that brings together many inspiring thought leaders and top organizations,” says Pat McCutcheon, CEO of MediPharm Labs.
“As a global leader in cannabis API supply, we are excited to share the latest in research and development of pharmaceutical cannabis derivative products.”
As a truly global medical cannabis company, MediPharm marks its international footprint with various operations across the globe. Through its wholesale and white label platforms, MediPharm formulates, consumer-tests, processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.
Most recently, MediPharm Labs has completed commercial exports to Australia. This year the company also recorded its first domestic sales in Australia after completing the commercialization of its manufacturing facility in MediPharm Labs Australia established in 2017.
We are very much excited to press forward a significant partnership with one of the cannabis industry’s leading global firms. Forging a lasting relationship with MediPharm Labs as a notable sponsor demonstrates how the upcoming 2020 Prohibitions Partners Live event on November 17- 20 is worth being a part of. It certainly attracts the industry’s most influential and pioneering cannabis companies across the globe – all in a four-day virtual conference.
Welcome aboard MediPharm Labs!